Stay updated with breaking news from Merck Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone Approval marks seventh...
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients ... | April 3, 2023
KEYTRUDA is approved for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors, as determined by an FDA-approved test, that have progressed... | March 29, 2023
04.12.2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and ...
This Is the First Anti-PD-1 Combination Approved as First-Line Treatment for These Patients Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose ...